病原体灭活：关于新技术的决策。共识会议报告。 - Suppr

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.

作者信息

Klein Harvey G, Anderson David, Bernardi Marie-Josée, Cable Ritchard, Carey William, Hoch Jeffrey S, Robitaille Nancy, Sivilotti Marco L A, Smaill Fiona

机构信息

Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

Transfusion. 2007 Dec;47(12):2338-47. doi: 10.1111/j.1537-2995.2007.01512.x.

DOI:10.1111/j.1537-2995.2007.01512.x

PMID:18036075

Abstract

摘要

相似文献

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.

Transfusion. 2007 Dec;47(12):2338-47. doi: 10.1111/j.1537-2995.2007.01512.x.

Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.

Vox Sang. 2007 Aug;93(2):179-82. doi: 10.1111/j.1423-0410.2007.00937.x.

The consensus development process in transfusion medicine: does it add value?

Transfusion. 2007 Dec;47(12):2176-9. doi: 10.1111/j.1537-2995.2007.01540.x.

Risk-based decision-making for blood safety: preliminary report of a consensus conference.

Vox Sang. 2011 Nov;101(4):277-81. doi: 10.1111/j.1423-0410.2011.01526.x. Epub 2011 Jul 22.

Health technology assessment in Europe.

Scand J Public Health. 2009 Jun;37(4):335-9. doi: 10.1177/1403494809105860.

Health technology assessment in Scotland.

Natl Med J India. 2003 Sep-Oct;16(5):275-6.

[When new methods are about to be introduced].

Tidsskr Nor Laegeforen. 2008 Feb 14;128(4):472.

International Association for Biologicals Symposium: "Advances in Transfusion Safety", Cambridge, UK. Foreword.

Biologicals. 2010 Jan;38(1):1. doi: 10.1016/j.biologicals.2009.10.003. Epub 2009 Dec 29.

Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.

Transfus Clin Biol. 2009 May;16(2):70-4. doi: 10.1016/j.tracli.2009.04.004. Epub 2009 May 7.

Assessment of the quality of mini-HTA.

Int J Technol Assess Health Care. 2009 Jan;25(1):42-8. doi: 10.1017/S0266462309090060.

引用本文的文献

Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.

Front Bioeng Biotechnol. 2022 Aug 23;10:908250. doi: 10.3389/fbioe.2022.908250. eCollection 2022.

Pathogen-reduction methods: advantages and limits.

ISBT Sci Ser. 2009 Mar;4(1):154-160. doi: 10.1111/j.1751-2824.2009.01224.x. Epub 2009 Feb 13.

Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets.

Br J Haematol. 2020 Feb;188(3):465-472. doi: 10.1111/bjh.16187. Epub 2019 Sep 30.

Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.

Front Med (Lausanne). 2018 May 7;5:129. doi: 10.3389/fmed.2018.00129. eCollection 2018.

Pathogen Inactivation of Cellular Blood Products-An Additional Safety Layer in Transfusion Medicine.

Front Med (Lausanne). 2017 Dec 4;4:219. doi: 10.3389/fmed.2017.00219. eCollection 2017.

Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Blood Transfus. 2017 Jul;15(4):357-364. doi: 10.2450/2017.0320-16. Epub 2017 May 11.

ALLOGENEIC PLATELET-RICH PLASMA FOR ROTATOR CUFF REPAIR.

Acta Ortop Bras. 2017 Jan-Feb;25(1):38-43. doi: 10.1590/1413-785220172501163417.

Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology.

Blood Transfus. 2018 Jul;16(4):348-351. doi: 10.2450/2017.0268-16. Epub 2017 Mar 23.

Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Blood Transfus. 2016 Jul;14(4):287-386. doi: 10.2450/2016.0065-16.

Pathogen inactivation technologies for cellular blood components: an update.

Transfus Med Hemother. 2014 Jul;41(4):309-25. doi: 10.1159/000365646. Epub 2014 Jul 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.

Transfusion. 2007 Dec;47(12):2338-47. doi: 10.1111/j.1537-2995.2007.01512.x.

Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.

Vox Sang. 2007 Aug;93(2):179-82. doi: 10.1111/j.1423-0410.2007.00937.x.

The consensus development process in transfusion medicine: does it add value?

Transfusion. 2007 Dec;47(12):2176-9. doi: 10.1111/j.1537-2995.2007.01540.x.

Risk-based decision-making for blood safety: preliminary report of a consensus conference.

Vox Sang. 2011 Nov;101(4):277-81. doi: 10.1111/j.1423-0410.2011.01526.x. Epub 2011 Jul 22.

Health technology assessment in Europe.

Scand J Public Health. 2009 Jun;37(4):335-9. doi: 10.1177/1403494809105860.

Health technology assessment in Scotland.

Natl Med J India. 2003 Sep-Oct;16(5):275-6.

[When new methods are about to be introduced].

Tidsskr Nor Laegeforen. 2008 Feb 14;128(4):472.

International Association for Biologicals Symposium: "Advances in Transfusion Safety", Cambridge, UK. Foreword.

Biologicals. 2010 Jan;38(1):1. doi: 10.1016/j.biologicals.2009.10.003. Epub 2009 Dec 29.

Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.

Transfus Clin Biol. 2009 May;16(2):70-4. doi: 10.1016/j.tracli.2009.04.004. Epub 2009 May 7.

Assessment of the quality of mini-HTA.

Int J Technol Assess Health Care. 2009 Jan;25(1):42-8. doi: 10.1017/S0266462309090060.

引用本文的文献

Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.

Front Bioeng Biotechnol. 2022 Aug 23;10:908250. doi: 10.3389/fbioe.2022.908250. eCollection 2022.

Pathogen-reduction methods: advantages and limits.

ISBT Sci Ser. 2009 Mar;4(1):154-160. doi: 10.1111/j.1751-2824.2009.01224.x. Epub 2009 Feb 13.

Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets.

Br J Haematol. 2020 Feb;188(3):465-472. doi: 10.1111/bjh.16187. Epub 2019 Sep 30.

Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.

Front Med (Lausanne). 2018 May 7;5:129. doi: 10.3389/fmed.2018.00129. eCollection 2018.

Pathogen Inactivation of Cellular Blood Products-An Additional Safety Layer in Transfusion Medicine.

Front Med (Lausanne). 2017 Dec 4;4:219. doi: 10.3389/fmed.2017.00219. eCollection 2017.

Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Blood Transfus. 2017 Jul;15(4):357-364. doi: 10.2450/2017.0320-16. Epub 2017 May 11.

ALLOGENEIC PLATELET-RICH PLASMA FOR ROTATOR CUFF REPAIR.

Acta Ortop Bras. 2017 Jan-Feb;25(1):38-43. doi: 10.1590/1413-785220172501163417.

Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology.

Blood Transfus. 2018 Jul;16(4):348-351. doi: 10.2450/2017.0268-16. Epub 2017 Mar 23.

Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Blood Transfus. 2016 Jul;14(4):287-386. doi: 10.2450/2016.0065-16.

Pathogen inactivation technologies for cellular blood components: an update.

Transfus Med Hemother. 2014 Jul;41(4):309-25. doi: 10.1159/000365646. Epub 2014 Jul 21.

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献